Search - tctmd.com

Displaying 21 - 40 of 69

Sort: Relevancy | Date

News Daily News

Rosuvastatin, Atorvastatin: Similar Efficacy in LODESTAR, Some Differing Signals

Yael L. Maxwell

October 19, 2023

News Opinion CV Team Dispatch

October 2023 News Roundup

L.A. McKeown

October 01, 2023

News Daily News

PET-Guided Strategy Lowers Risk, Boosts Outcomes in Stable CAD: CENTURY

Michael O'Riordan

September 29, 2023

News Daily News

TCTMD’s Top 10 Most Popular Stories for April 2023

Shelley Wood

April 28, 2023

News Daily News

Inactivity Pandemic Poised to Undo CVD Prevention Advances

Michael O'Riordan

April 11, 2023

News Conference News ACC 2023

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

Michael O'Riordan

March 14, 2023

News Conference News ACC 2023

Keto Diet Linked to Hypercholesterolemia, Higher ASCVD Risk

Shelley Wood

March 08, 2023

News Conference News ACC 2023

Multifaceted Approach to COORDINATE Diabetes Care Improves GDMT

Yael L. Maxwell

March 07, 2023

News Conference News ISET 2023

‘Who’s In Charge of a Wound?’: Interventionalists Should Play a Role

Caitlin E. Cox

January 18, 2023

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

Shelley Wood

August 22, 2022

News Daily News

Mediterranean Diet Bests Low Fat for Secondary Prevention: CORDIOPREV

Michael O'Riordan

May 09, 2022

News Opinion Editor's Corner AHA 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

Shelley Wood

November 08, 2021

News Opinion CV Team Dispatch

November 2021 News Roundup

L.A. McKeown

November 01, 2021

News Daily News

AHA Seeks to Drive Down Amputations 20% by 2030

L.A. McKeown

April 01, 2021

News Daily News

Despite COVID-19, Heart Disease Remains Top US Killer: AHA

Michael O'Riordan

January 28, 2021

News Daily News

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Shelley Wood

December 17, 2020

News Daily News

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Michael O'Riordan

September 24, 2020

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

News Daily News

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Yael L. Maxwell

December 20, 2019

News Conference News AHA 2019

Dapagliflozin Has Benefits Across Heart Failure Subgroups

Todd Neale

November 17, 2019

Advertisement

Rosuvastatin, Atorvastatin: Similar Efficacy in LODESTAR, Some Differing Signals

October 2023 News Roundup

PET-Guided Strategy Lowers Risk, Boosts Outcomes in Stable CAD: CENTURY

TCTMD’s Top 10 Most Popular Stories for April 2023

Inactivity Pandemic Poised to Undo CVD Prevention Advances

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

Keto Diet Linked to Hypercholesterolemia, Higher ASCVD Risk

Multifaceted Approach to COORDINATE Diabetes Care Improves GDMT

‘Who’s In Charge of a Wound?’: Interventionalists Should Play a Role

What’s Going to Be Hot at ESC 2022?

Mediterranean Diet Bests Low Fat for Secondary Prevention: CORDIOPREV

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

November 2021 News Roundup

AHA Seeks to Drive Down Amputations 20% by 2030

Despite COVID-19, Heart Disease Remains Top US Killer: AHA

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Dapagliflozin Has Benefits Across Heart Failure Subgroups

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content